The Relation of Microtubule-Associated Protein 2 and Cell Migration

  • participants needed
  • sponsor
    National Taiwan University Hospital
Updated on 7 November 2020


Clarify the relation of microtubule-associated protein 2 and cell migration


Betel quid chewing has been shown to have intimate correlation with oral cancer. In Taiwan, the incidence of oral cancer is the fourth most common malignancy in male and in fact, 90% of which has been linked to betel quid chewing. The predisposing factors in oral cancers between the western countries and India, Southeast Asia including Taiwan are different. The factor is smoking in the former countries and betel quid chewing is the most important one in the latter groups. The genetic aberrations of oral cancers are different too between the western countries and India, Southeast Asia including Taiwan. The percentage of RAS mutations of oral cancers in the western countries is around 5%, and 35% in the India. In Taiwan, the RAS mutation rate revealed with immunohistochemical staining is 92%, comparing with those in western countries (62%), Japan (55-65%) and vice versa in the p53 mutations. The percentage of p53 mutations of oral cancers in the western countries is around 50%, and 16% in the India, Southeast Asia and Taiwan. It is generally believed that betel nut itself, arecoline and arecaidine, the major betel alkaloids, account for the etiological factors in the pathogenesis of oral cancer while betel quid supplements, unlike the former two main components, were reported to have little relevancy to oral cancer. Despite the fact that the cytotoxic and genotoxic effects of betel nut extract and arecoline, arecaidine have been extensively documented, and that some well-studied oncogenes or tumor suppressor genes have been implicated in betel quid-related oral cancer, the molecular mechanisms, addressed in a broader view, by which betel nut ingredients lead to oral tumorigenesis are not fully understood. Our preliminary results, by virtue of different genome-wide screening approaches to explore cellular functions of protein kinases in this context, identified several candidates that showed differential expression upon treatment of BQ on primary cultures from human oral mucosa. Of the candidates isolated, microtubule-associated protein 2 (MAP2), a neuron-specific cytoskeletal protein that is thought to predominantly express in rat brain cells, was found up-regulated at RNA level by RT-PCR in primary cultures. Our expanded immunohistochemical results of normal mucosa, leukoplakia and oral squamous cell carcinoma (OSCC) suggest that expression of the MAP2 significantly correlates with progression of BQ-induced OSCC (P = 0.0046), since the percentage of MAP2 positive staining is as much fourfold in BQ-exposed OSCC (41.2%) as in BQ-free OSCC (10.5%), whereas normal mucosa and leukoplakia show much less immunoreactivity as a whole. Furthermore, the MAP2 is shown to be preferentially expressed in histopathologically less differentiated OSCC (P = 0.014). Finally, we show that the MAP2 is highly expressed in the majority of invasive OSCC (67%). Consequently, this finding, in conjunction with the previous one, raise a possibility that overexpression of the MAP2 may play a critical role in the development of highly malignant OSCC characteristic of invasive and/or metastatic. Here we study the issue by establishing an in vitro system where extracts from the whole betel quid sandwiches are used to treat head and neck cancer cell lines and primary oral epithelial cells and subsequently, the effects of such treatments will be evaluated in terms of cell migration, Western blotting. Eight head and neck cancer cell lines and normal oral mucosae from 8 patients undergoing oral surgery will be collected. Extracts from the whole betel quid sandwiches with the concentration of 1.5 mg/ml will be added to the cell lines and primary oral epithelial cells for 1,3 and 5 days, respectively. Migration assay and detection of MAP2 expression will be performed to elucidate the relationship of MAP2 and cell migration.

Condition Oral Neoplasm
Clinical Study IdentifierNCT00174109
SponsorNational Taiwan University Hospital
Last Modified on7 November 2020


How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note